Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Which should be added to cisplatin for advanced non-small-cell lung cancer—vinorelbine or gemcitabine?

Nature Clinical Practice Oncology volume 2, pages 190–191 (2005)Cite this article

boxed-textMartoni A et al. (2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41: 81–92

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Delbaldo C et al. (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292: 470–484

    Article  CAS  Google Scholar 

  2. Rigas JR (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9 (Suppl 2): 16–23

    Article  CAS  Google Scholar 

  3. Breathnach OS et al. (2001) Twenty-two years of phase iii trials for patients with advanced non–small-cell lung cancer: sobering results. J Clin Oncol 19: 1734–1742

    Article  CAS  Google Scholar 

  4. Le Chevalier T et al. (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47: 69–80

    Article  CAS  Google Scholar 

  5. Novello S et al. Cost-minimization analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin, and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer, in press

  6. Ramsey SD et al. (2002) Economic analysis of vinorelbine/cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 94: 291–297

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Department of Clinical and Biological Sciences, Respiratory Medicine, at the University of Turin, and Director of the Thoracic Oncology Unit at S. Luigi Hospital, Orbassano, Turin, Italy

    Giorgio V Scagliotti

Authors
  1. Giorgio V Scagliotti
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

GV Scagliotti is a consultant for AstraZeneca and Eli Lilly and is on Speaker Programs for Aventis, AstraZeneca, Eli Lilly, Millennium and J&J.

Glossary

KARNOFSKY PERFORMANCE STATUS (KPS)

A 0–100 scoring system to assess the wellbeing of cancer patients and their ability to perform ordinary tasks

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scagliotti, G. Which should be added to cisplatin for advanced non-small-cell lung cancer—vinorelbine or gemcitabine?. Nat Rev Clin Oncol 2, 190–191 (2005). https://doi.org/10.1038/ncponc0137

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncponc0137

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing